262 related articles for article (PubMed ID: 35488106)
1. Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation.
Pianko MJ; Golob JL
Cancer Metastasis Rev; 2022 Jun; 41(2):367-382. PubMed ID: 35488106
[TBL] [Abstract][Full Text] [Related]
2. The Gut Microbiota and Hematopoietic Stem Cell Transplantation: Challenges and Potentials.
Noor F; Kaysen A; Wilmes P; Schneider JG
J Innate Immun; 2019; 11(5):405-415. PubMed ID: 30286447
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications.
Zhang L; Xiang Y; Li Y; Zhang J
Front Immunol; 2022; 13():1058272. PubMed ID: 36569873
[TBL] [Abstract][Full Text] [Related]
4. The contribution of the intestinal microbiome to immune recovery after HCT.
Wolfe AE; Markey KA
Front Immunol; 2022; 13():988121. PubMed ID: 36059482
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects and applications of the gut microbiome in hematologic malignancies.
D'Angelo CR; Sudakaran S; Callander NS
Cancer; 2021 Mar; 127(5):679-687. PubMed ID: 33369893
[TBL] [Abstract][Full Text] [Related]
6. Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation.
Ciernikova S; Kasperova B; Drgona L; Smolkova B; Stevurkova V; Mego M
Blood Rev; 2021 Jul; 48():100790. PubMed ID: 33573867
[TBL] [Abstract][Full Text] [Related]
7. Microbiome and diversity indices during blood stem cells transplantation - new perspectives?
Parco S; Benericetti G; Vascotto F; Palmisciano G
Cent Eur J Public Health; 2019 Dec; 27(4):335-339. PubMed ID: 31951695
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation.
Fujiwara H
Front Immunol; 2021; 12():703298. PubMed ID: 34512627
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease.
Yue X; Zhou H; Wang S; Chen X; Xiao H
Cancer Med; 2024 Feb; 13(3):e6799. PubMed ID: 38239049
[TBL] [Abstract][Full Text] [Related]
10. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.
Li J; Zhang X; Chen Y; Zheng Q; Zhao M; Jiang H
Oxid Med Cell Longev; 2022; 2022():2124627. PubMed ID: 35571252
[TBL] [Abstract][Full Text] [Related]
13. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
14. The Microbiome and Pediatric Transplantation.
Elgarten CW; Margolis EB; Kelly MS
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S80-S89. PubMed ID: 38417089
[TBL] [Abstract][Full Text] [Related]
15. Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure.
Uribe-Herranz M; Klein-González N; Rodríguez-Lobato LG; Juan M; de Larrea CF
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498529
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
van Lier YF; Vos J; Blom B; Hazenberg MD
Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
[TBL] [Abstract][Full Text] [Related]
17. Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic hematopoietic stem cell transplantation.
Ingham AC; Kielsen K; Cilieborg MS; Lund O; Holmes S; Aarestrup FM; Müller KG; Pamp SJ
Microbiome; 2019 Sep; 7(1):131. PubMed ID: 31519210
[TBL] [Abstract][Full Text] [Related]
18. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them.
Chhabra S; Szabo A; Glisch C; George G; Narra RK; Harrington A; Jerkins JH; D'Souza A; Dhakal B; Pasquini MC; Hamadani M; Hari PN
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1288-1297. PubMed ID: 32135202
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
